Troikaa Pharmaceuticals

Troikaa Pharmaceuticals Ltd. is an Indian multinational pharmaceutical company headquartered in Ahmedabad, Gujarat in India.[1][2][3]

Troikaa Pharmaceuticals Ltd.
TypePrivate
IndustryPharmaceuticals
Founded1983
FounderMr. Rajni V. Patel
Headquarters
Ahmedabad, Gujarat
,
India
Area served
Worldwide
Key people
Ketan R. Patel (Chairman & managing director) Milan R. Patel (Joint Managing Director)
ProductsPharmaceuticals, Branded and Generic drugs,
Number of employees
2300+ (2019)
Websitewww.troikaa.com

History

Troikaa Pharmaceuticals limited was established in 1983 in Ahmedabad, Gujarat by Rajni V. Patel, one of the few pharmacy graduates of the first batch of L. M. College of Pharmacy, Ahmedabad in 1950. Ketan R. Patel is the current Chairman & Managing Director of the company. Milan R. Patel is Joint Managing Director of the company.

Litigation

In 2016, Troikaa Pharmaceuticals filed a petition in Delhi High Court seeking license cancellation of Diclofenac Sodium Injection 75 mg/ml, manufactured by Themis Medicare Pvt Ltd and marketed by Novartis India Ltd. under the brand name Voveran 1ml.[4][5] Troikaa claimed that the diclofenac sodium 75 mg/ml injection contained Transcutol-P which caused damage to the kidneys. In July 2018, India's Drug Regulator canceled the license granted to M/S Themis Medicare for the sale of Diclofenac injection 75 mg/ml containing Transcutol-P.[6][7]

In 2012, Troikaa Pharmaceuticals filed a patent infringement suit in Ahmedabad district court against Ahmedabad-based Lincoln Pharmaceuticals and Delhi-based Akums Drug & Pharmaceuticals Ltd, saying the two companies had infringed upon its patented high concentration, low viscosity diclofenac injection. The case was continued by Gujarat High Court, and ordered to Akums Drugs not to infringe, and dismissed Linclon Pharma's appeal.[8]

In 2008, Troikaa filed a suit for infringement of design against a company manufacturing D-shaped tablets. The company had challenged that Troikaa's D shaped tablet registration was invalid. The suit was transferred to the High Court of Gujarat and later in its first case under the Designs Act, the High Court decided in favor of the Troikaa.[9]

Awards & honors

Research Articles
  • DYNAPAR AQ IV BOLUS INJECTION FOR POSTOPERATIVE PAIN, ISSN 0975-8232, Sanjay Kumar H. Maroo, P.N. Kakar, Anil K. Varshney, B.M. Subnis, Jaishri A. Bogra, Shubha N. Mohite. 2017
  • PENETRATION OF DICLOFENAC FROM NOVEL QUICK PENETRATING SOLUTION. A COMPARATIVE SCINTIGRAPHY STUDY WITH GEL, Sanjaykumar H. Maroo *1, Ketan R. Patel 2 and Aseem Bhatnagar, International Journal of Pharma & Science Res.2013;5(4):175-178
  • A Comparative Dermal Microdialysis Study of Diclofenac QPS versus Conventional 1% Diclofenac Gel, Sanjay Kumar H. Maroo1*, Ketan R. Patel1, Vipul Prajapati, Rajen Shah, Milind Bagul, Rakesh U. Ojha, ISSN 0975-248X, 2013, vol5, issue4
  • Comparison of Heparin Quick Penetrating Solution and Diclofenac Quick Penetrating Solution for the Prevention of Superficial Thrombophlebitis Caused by Peripheral Venous Cannulation: A Randomized Double-Blind Study, Akhileshwar and Swati Singh, doi: 10.4103/aer.AER_189_18, 2019 Jan-Mar; 13(1): 155–157, PMID 31031497
  • NOVEL TOPICAL QUICK PENETRATING SOLUTION OF HEPARIN IN MANAGEMENT OF SUPERFICIAL THROMBOPHLEBITIS: RESULTS OF RANDOMIZED ACTIVE CONTROLLED TRIAL, Avinash Supe, B.M. Subnis, M. Rajeev Rao, Vasantray H. Panchal, R. J. Lakhani, ISSN 0975-8232, 2017

References
  1. "National Technology Day Celebration". pib.nic.in.
  2. "Troikaa's Dynapar QPS bags National Award". BPD. 10 June 2015.
  3. Das, Sohini (1 October 2014). "Drug cos bet on NDDS for better price, market share". Business Standard India.
  4. Raghavan, Prabha (19 May 2016). "Indian pharma company may sue drug controller over safety of Novartis painkiller". The Economic Times.
  5. Thacker, Teena (11 July 2018). "Drug regulator orders recall of Novartis's painkiller diclofenac". livemint.com.
  6. India, Press Trust of (12 July 2018). "Drug regulator cancels licence for Diclofenac sold by Novartis". Business Standard India.
  7. "'Novartis, Themis use unsafe ingredient' - BUSINESS & ECONOMY - News | News Syndication | Content Syndication". dnasyndication.com.
  8. Dutta, Vishal (30 April 2012). "HC grants relief to Troikaa in patent case; restrains two firms from selling Dynapar injections". The Economic Times.
  9. Reddy, Prashant. "Gujarat High Court grants interim injunction in Designs Case". SpicyIP.
  10. "Technology Development Board 20th Annual Report 2015-16" (PDF). tdb.gov.in. Govet of India.
  11. "National Technology Day Celebration". pib.nic.in.
  12. "Troikaa bags recognition from Govt of India". BPD. 1 March 2018.
  13. "Troikaa wins award for IP Excellence". Daily News and Analysis. Ahmedabad. Zee Media. 12 Dec 2018. p. 4.
  14. "Troika receiving the IPA-ACG innovation in Solid Dosage form Award" (July 2015). Ahmedabad: Pharma Times. 7 July 2015. p. 9.
  15. "DSIR : Department of Scientific and Industrial Research". www.dsir.gov.in.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.